Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis

NCT05633563 is registered in ClinicalTrials.gov with Steen Hvitfeldt Poulsen as lead sponsor.

NCT NCT05633563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05633563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis
Lead sponsor
Steen Hvitfeldt Poulsen
Phase
Phase 4
Overall status
Completed
Start date
October 1, 2021
Completion date
June 1, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mitochondrial pathology, transthyretin amyloid cardiopathy